

Sanjay Asthana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11559003/publications.pdf>

Version: 2024-02-01

277
papers

15,754
citations

20797

60
h-index

21521

114
g-index

346
all docs

346
docs citations

346
times ranked

19428
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	9.4	1,962
2	Gut microbiome alterations in Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 13537.	1.6	1,256
3	Rare coding variants in PLCC2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	9.4	783
4	Preserved Cognition in Patients With Early Alzheimer Disease and Amnesic Mild Cognitive Impairment During Treatment With Rosiglitazone: A Preliminary Study. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 950-958.	0.6	498
5	Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 33.	3.8	488
6	Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS Cognitive and Affective Study. <i>PLoS Medicine</i> , 2015, 12, e1001833.	3.9	330
7	Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middle-Aged Adults at Risk for Alzheimer Disease. <i>JAMA Neurology</i> , 2015, 72, 1013.	4.5	305
8	Enhancement of Memory in Alzheimer Disease With Insulin and Somatostatin, but Not Glucose. <i>Archives of General Psychiatry</i> , 1999, 56, 1135.	13.8	287
9	The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 124.	3.0	273
10	Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. <i>Psychoneuroendocrinology</i> , 2003, 28, 809-822.	1.3	233
11	Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. <i>Psychoneuroendocrinology</i> , 1999, 24, 657-678.	1.3	225
12	Insulin resistance predicts brain amyloid deposition in late middle-aged adults. <i>Alzheimer's and Dementia</i> , 2015, 11, 504.	0.4	196
13	Amyloid burden is associated with self-reported sleep in nondemented late middle-aged adults. <i>Neurobiology of Aging</i> , 2015, 36, 2568-2576.	1.5	183
14	Physical activity attenuates age-related biomarker alterations in preclinical AD. <i>Neurology</i> , 2014, 83, 1753-1760.	1.5	181
15	Sex biology contributions to vulnerability to Alzheimer's disease: A think tank convened by the Women's Alzheimer's Research Initiative. <i>Alzheimer's and Dementia</i> , 2016, 12, 1186-1196.	0.4	180
16	Insulin Effects on Glucose Metabolism, Memory, and Plasma Amyloid Precursor Protein in Alzheimer's Disease Differ According to Apolipoprotein-E Genotype. <i>Annals of the New York Academy of Sciences</i> , 2000, 903, 222-228.	1.8	175
17	Insulin Resistance, Brain Atrophy, and Cognitive Performance in Late Middle-Aged Adults. <i>Diabetes Care</i> , 2013, 36, 443-449.	4.3	173
18	The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 130-142.	1.2	169

#	ARTICLE	IF	CITATIONS
19	Amyloid burden and neural function in people at risk for Alzheimer's Disease. <i>Neurobiology of Aging</i> , 2014, 35, 576-584.	1.5	166
20	Transethnic genome-wide scan identifies novel Alzheimer's disease loci. <i>Alzheimer's and Dementia</i> , 2017, 13, 727-738.	0.4	166
21	Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. <i>Neurology</i> , 2017, 89, 445-453.	1.5	166
22	Reduced hippocampal activation during episodic encoding in middle-aged individuals at genetic risk of Alzheimer's Disease: a cross-sectional study. <i>BMC Medicine</i> , 2006, 4, 1.	2.3	152
23	The Influence of Alzheimer Disease Family History and Apolipoprotein E ϵ 4 on Mesial Temporal Lobe Activation. <i>Journal of Neuroscience</i> , 2006, 26, 6069-6076.	1.7	152
24	Insulin Metabolism in Alzheimer's Disease Differs According to Apolipoprotein E Genotype and Gender. <i>Neuroendocrinology</i> , 1999, 70, 146-152.	1.2	147
25	Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2017, 74, 41.	4.5	147
26	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. <i>JAMA Neurology</i> , 2021, 78, 102.	4.5	144
27	Magnetic Resonance Imaging Characterization of Brain Structure and Function in Mild Cognitive Impairment: A Review. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 920-934.	1.3	130
28	Associations between white matter microstructure and amyloid burden in preclinical Alzheimer's disease: A multimodal imaging investigation. <i>NeuroImage: Clinical</i> , 2014, 4, 604-614.	1.4	119
29	Low cerebral blood flow is associated with lower memory function in metabolic syndrome. <i>Obesity</i> , 2013, 21, 1313-1320.	1.5	117
30	Neurobiological Underpinnings of the Estrogen - Mood Relationship. <i>Current Psychiatry Reviews</i> , 2012, 8, 247-256.	0.9	117
31	Anosognosia in mild cognitive impairment: Relationship to activation of cortical midline structures involved in self-appraisal. <i>Journal of the International Neuropsychological Society</i> , 2007, 13, 450-61.	1.2	109
32	White matter is altered with parental family history of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2010, 6, 394-403.	0.4	109
33	Microstructural white matter alterations in preclinical Alzheimer's disease detected using free water elimination diffusion tensor imaging. <i>PLoS ONE</i> , 2017, 12, e0173982.	1.1	104
34	The effect of TOMM40 poly- ϵ T length on gray matter volume and cognition in middle-aged persons with APOE ϵ 3/ ϵ 3 genotype. <i>Alzheimer's and Dementia</i> , 2011, 7, 456-465.	0.4	103
35	Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 873-886.	1.2	101
36	Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age. <i>Brain</i> , 2020, 143, 320-335.	3.7	100

#	ARTICLE	IF	CITATIONS
37	The Kronos Early Estrogen Prevention Study (KEEPS). <i>Menopause</i> , 2019, 26, 1071-1084.	0.8	97
38	Occupational Complexity and Cognitive Reserve in a Middle-Aged Cohort at Risk for Alzheimer's Disease. <i>Archives of Clinical Neuropsychology</i> , 2015, 30, 634-642.	0.3	96
39	Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid- β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 473-484.	1.2	93
40	Estrogen and Alzheimer's Disease. <i>Drugs and Aging</i> , 2002, 19, 405-427.	1.3	92
41	Subjective memory complaints, cortical thinning, and cognitive dysfunction in middle-aged adults at risk of AD. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 33-40.	1.2	90
42	Effect of parental family history of Alzheimer's disease on serial position profiles. <i>Alzheimer's and Dementia</i> , 2008, 4, 285-290.	0.4	88
43	Effects of Simvastatin on Cerebrospinal Fluid Biomarkers and Cognition in Middle-Aged Adults at Risk for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2008, 13, 187-197.	1.2	88
44	Cerebral Blood Flow is Diminished in Asymptomatic Middle-Aged Adults with Maternal History of Alzheimer's Disease. <i>Cerebral Cortex</i> , 2014, 24, 978-988.	1.6	85
45	Cardiorespiratory fitness is associated with brain structure, cognition, and mood in a middle-aged cohort at risk for Alzheimer's disease. <i>Brain Imaging and Behavior</i> , 2015, 9, 639-649.	1.1	85
46	CSF T-Tau/A β 242 Predicts White Matter Microstructure in Healthy Adults at Risk for Alzheimer's Disease. <i>PLoS ONE</i> , 2012, 7, e37720.	1.1	84
47	A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women. <i>Age and Ageing</i> , 2008, 38, 86-93.	0.7	82
48	Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 385-397.	1.2	81
49	Short-term Hormone Therapy with Transdermal Estradiol Improves Cognition for Postmenopausal Women with Alzheimer's Disease: Results of a Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 495-505.	1.2	80
50	Association of Neighborhood-Level Disadvantage With Cerebral and Hippocampal Volume. <i>JAMA Neurology</i> , 2020, 77, 451.	4.5	80
51	An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, 431-445.	0.4	80
52	The influence of parental history of Alzheimer's disease and apolipoprotein E ϵ 4 on the BOLD signal during recognition memory. <i>Brain</i> , 2008, 132, 383-391.	3.7	79
53	Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers. <i>Neurology</i> , 2017, 89, 1782-1788.	1.5	76
54	Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease. <i>JAMA Neurology</i> , 2015, 72, 699.	4.5	75

#	ARTICLE	IF	CITATIONS
55	Cognitive Effects of Soy Isoflavones in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 1009-1019.	1.2	74
56	Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 38-41.	1.5	73
57	ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. <i>Neurology</i> , 2019, 92, e1567-e1579.	1.5	73
58	Measuring longitudinal cognition: Individual tests versus composites. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 74-84.	1.2	69
59	Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease. <i>Psychopharmacology</i> , 1993, 112, 421-427.	1.5	68
60	Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOE ε4 Carriers. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 525-533.	1.2	65
61	Association between enrollment factors and incident cognitive impairment in Blacks and Whites: Data from the Alzheimer's Disease Center. <i>Alzheimer's and Dementia</i> , 2019, 15, 1533-1545.	0.4	64
62	Preserved Cognition in Patients With Early Alzheimer Disease and Amnesic Mild Cognitive Impairment During Treatment With Rosiglitazone. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 950-958.	0.6	62
63	Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS cognitive and affective sub study (KEEPS Cog). <i>Brain Research</i> , 2013, 1514, 12-17.	1.1	62
64	Effects of hormone therapy on cognition and mood. <i>Fertility and Sterility</i> , 2014, 101, 898-904.	0.5	62
65	Age-dependent differences in brain tissue microstructure assessed with neurite orientation dispersion and density imaging. <i>Neurobiology of Aging</i> , 2016, 43, 79-88.	1.5	61
66	Cortical Microstructural Alterations in Mild Cognitive Impairment and Alzheimer's Disease Dementia. <i>Cerebral Cortex</i> , 2020, 30, 2948-2960.	1.6	61
67	Beta-amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention study. <i>Alzheimer's and Dementia</i> , 2016, 12, 805-814.	0.4	59
68	Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 299-309.	2.3	58
69	fMRI activation during episodic encoding and metacognitive appraisal across the lifespan: Risk factors for Alzheimer's disease. <i>Neuropsychologia</i> , 2008, 46, 1667-1678.	0.7	58
70	The Effects of Ramipril in Individuals at Risk for Alzheimer's Disease: Results of a Pilot Clinical Trial. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 147-156.	1.2	58
71	Potential Role of Muscarinic Agonists in Alzheimer's Disease. <i>Drugs and Aging</i> , 1997, 11, 450-459.	1.3	57
72	Cerebrospinal fluid sphingolipids, β2-amyloid, and tau in adults at risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 2486-2494.	1.5	57

#	ARTICLE	IF	CITATIONS
73	Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. <i>Neurology</i> , 2018, 90, e1404-e1412.	1.5	57
74	<i>BDNF</i> Val66Met predicts cognitive decline in the Wisconsin Registry for Alzheimer's Prevention. <i>Neurology</i> , 2017, 88, 2098-2106.	1.5	52
75	Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 276-282.	2.3	51
76	Clinical Pharmacology and Differential Cognitive Efficacy of Estrogen Preparations. <i>Annals of the New York Academy of Sciences</i> , 2005, 1052, 93-115.	1.8	51
77	Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1373-1383.	1.2	51
78	Moderate intensity physical activity associates with CSF biomarkers in a cohort at risk for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 188-195.	1.2	51
79	Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition. <i>Journal of the International Neuropsychological Society</i> , 2015, 21, 841-850.	1.2	49
80	Effects of long-term testosterone administration on cognition in older men with low or low-to-normal testosterone concentrations: a prespecified secondary analysis of data from the randomised, double-blind, placebo-controlled TEAAM trial. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 657-665.	5.5	49
81	Relationships between cardiorespiratory fitness, hippocampal volume, and episodic memory in a population at risk for Alzheimer's disease. <i>Brain and Behavior</i> , 2017, 7, e00625.	1.0	49
82	Participation in cognitively-stimulating activities is associated with brain structure and cognitive function in preclinical Alzheimer's disease. <i>Brain Imaging and Behavior</i> , 2015, 9, 729-736.	1.1	48
83	Mild Cognitive Impairment in Late Middle Age in the Wisconsin Registry for Alzheimer's Prevention Study: Prevalence and Characteristics Using Robust and Standard Neuropsychological Normative Data. <i>Archives of Clinical Neuropsychology</i> , 2016, 31, 675-688.	0.3	48
84	In-depth Site-specific Analysis of N-glycoproteome in Human Cerebrospinal Fluid and Glycosylation Landscape Changes in Alzheimer's Disease. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100081.	2.5	48
85	Low HDL cholesterol is associated with lower gray matter volume in cognitively healthy adults. <i>Frontiers in Aging Neuroscience</i> , 2010, 2, .	1.7	47
86	Effects of hormone therapy on brain structure. <i>Neurology</i> , 2016, 87, 887-896.	1.5	47
87	Medial prefrontal functional connectivity's Relation to memory self-appraisal accuracy in older adults with and without memory disorders. <i>Neuropsychologia</i> , 2012, 50, 603-611.	0.7	46
88	Vitamin E and memantine in Alzheimer's disease: Clinical trial methods and baseline data. <i>Alzheimer's and Dementia</i> , 2014, 10, 36-44.	0.4	46
89	Insulin resistance is associated with lower arterial blood flow and reduced cortical perfusion in cognitively asymptomatic middle-aged adults. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 2249-2261.	2.4	46
90	Cerebrospinal fluid ratios with A β ₄₂ predict preclinical brain A β amyloid accumulation. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 2, 27-38.	1.2	44

#	ARTICLE	IF	CITATIONS
91	DNA Hypomethylation in Blood Links B3GALT4 and ZADH2 to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 927-934.	1.2	43
92	Amyloid duration is associated with preclinical cognitive decline and tau PET. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12007.	1.2	43
93	Age-accelerated cognitive decline in asymptomatic adults with CSF β -amyloid. <i>Neurology</i> , 2018, 90, e1306-e1315.	1.5	42
94	Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife. <i>Brain</i> , 2016, 139, 2261-2274.	3.7	41
95	Associations between Performance on Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1395-1408.	1.2	40
96	<i>KLOTHO</i> heterozygosity attenuates <i>APOE4</i> -related amyloid burden in preclinical AD. <i>Neurology</i> , 2019, 92, e1878-e1889.	1.5	40
97	Neuropsychiatric symptoms in dementia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 167, 437-454.	1.0	40
98	Structural MRI discriminates individuals with Mild Cognitive Impairment from age-matched controls: A combined neuropsychological and voxel based morphometry study. , 2006, 2, ALZJALZ200606001.		39
99	Neuropsychiatric Symptoms and Caregiver Burden in Individuals With Alzheimer's Disease: The TEAM-AD VA Cooperative Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2018, 31, 177-185.	1.2	39
100	Moderate Physical Activity is Associated with Cerebral Glucose Metabolism in Adults at Risk for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 1089-1097.	1.2	38
101	Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia. <i>Neurology</i> , 2018, 91, e436-e443.	1.5	38
102	Hypertension and obesity moderate the relationship between β -amyloid and cognitive decline in midlife. <i>Alzheimer's and Dementia</i> , 2019, 15, 418-428.	0.4	38
103	Effect of Alzheimer Disease Risk on Brain Function During Self-appraisal in Healthy Middle-aged Adults. <i>Archives of General Psychiatry</i> , 2007, 64, 1163.	13.8	35
104	Cardiorespiratory fitness alters the influence of a polygenic risk score on biomarkers of AD. <i>Neurology</i> , 2017, 88, 1650-1658.	1.5	35
105	Amyloid burden, cortical thickness, and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 160-169.	1.2	34
106	Associative Learning Over Trials Activates the Hippocampus in Healthy Elderly but not Mild Cognitive Impairment. <i>Aging, Neuropsychology, and Cognition</i> , 2008, 15, 129-145.	0.7	33
107	Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. <i>Molecular Neurodegeneration</i> , 2020, 15, 57.	4.4	33
108	Impact of sex and <i>APOE</i> ϵ 4 on age-related cerebral perfusion trajectories in cognitively asymptomatic middle-aged and older adults: A longitudinal study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 3016-3027.	2.4	33

#	ARTICLE	IF	CITATIONS
109	Masculine Vitality: Pros and Cons of Testosterone in Treating the Andropause. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2004, 59, M461-M465.	1.7	32
110	Association of longitudinal white matter degeneration and cerebrospinal fluid biomarkers of neurodegeneration, inflammation and Alzheimer's disease in late-middle-aged adults. <i>Brain Imaging and Behavior</i> , 2019, 13, 41-52.	1.1	32
111	Association of Neighborhood Context, Cognitive Decline, and Cortical Change in an Unimpaired Cohort. <i>Neurology</i> , 2021, 96, e2500-e2512.	1.5	32
112	Macrovascular and microvascular cerebral blood flow in adults at risk for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 7, 48-55.	1.2	31
113	Label-free quantitative comparison of cerebrospinal fluid glycoproteins and endogenous peptides in subjects with Alzheimer's disease, mild cognitive impairment, and healthy individuals. <i>Proteomics - Clinical Applications</i> , 2016, 10, 1225-1241.	0.8	30
114	Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 79-89.	1.2	30
115	Awareness of Memory Abilities in Community-Dwelling Older Adults with Suspected Dementia and Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 30, 83-92.	0.7	28
116	Intracranial arterial four-dimensional flow is associated with metrics of brain health and Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 420-428.	1.2	28
117	Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the Alzheimer's disease continuum. <i>NeuroImage: Clinical</i> , 2019, 23, 101895.	1.4	28
118	Cerebrospinal fluid metabolomics identifies 19 brain-related phenotype associations. <i>Communications Biology</i> , 2021, 4, 63.	2.0	28
119	Effects of Atorvastatin on Cerebral Blood Flow in Middle-Aged Adults at Risk for Alzheimer's Disease: A Pilot Study. <i>Current Alzheimer Research</i> , 2012, 9, 990-997.	0.7	27
120	Meeting physical activity recommendations may be protective against temporal lobe atrophy in older adults at risk for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 4, 14-17.	1.2	27
121	Fitness, independent of physical activity is associated with cerebral blood flow in adults at risk for Alzheimer's disease. <i>Brain Imaging and Behavior</i> , 2020, 14, 1154-1163.	1.1	27
122	Frontiers proposal. National Institute on Aging "bench to bedside: estrogen as a case study". <i>Age</i> , 2009, 31, 199-210.	3.0	25
123	The KEEPS-Cognitive and Affective Study: Baseline Associations between Vascular Risk Factors and Cognition. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 331-341.	1.2	25
124	A Pilot Study of Perceived Mouth Dryness, Perceived Swallowing Effort, and Saliva Substitute Effects in Healthy Adults Across the Age Range. <i>Dysphagia</i> , 2018, 33, 200-205.	1.0	25
125	17beta-estradiol reduces plasma Abeta40 for HRT-naïve postmenopausal women with Alzheimer disease: a preliminary study. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 239-44.	0.6	25
126	Cerebrospinal fluid biomarkers of neurofibrillary tangles and synaptic dysfunction are associated with longitudinal decline in white matter connectivity: A multi-resolution graph analysis. <i>NeuroImage: Clinical</i> , 2019, 21, 101586.	1.4	24

#	ARTICLE	IF	CITATIONS
127	Amyloid Burden, Neuronal Function, and Cognitive Decline in Middle-Aged Adults at Risk for Alzheimer's Disease. <i>Journal of the International Neuropsychological Society</i> , 2014, 20, 422-433.	1.2	23
128	Cognitive variabilityâ€”A marker for incident MCI and AD: An analysis for the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 4, 47-55.	1.2	22
129	Differential effects of neurodegeneration biomarkers on subclinical cognitive decline. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 129-138.	1.8	22
130	Inflammation, tau pathology, and synaptic integrity associated with sleep spindles and memory prior to β -amyloid positivity. <i>Sleep</i> , 2022, 45, .	0.6	22
131	Effects of Insulin and Octreotide on Memory and Growth Hormone in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 18, 595-602.	1.2	21
132	Effects of acute infusion of the muscarinic cholinergic agonist arecoline on verbal memory and visuo-spatial function in dementia of the alzheimer type. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1991, 15, 643-648.	2.5	20
133	Neuroendocrine responses to intravenous infusion of arecoline in patients with Alzheimer's disease. <i>Psychoneuroendocrinology</i> , 1995, 20, 623-636.	1.3	19
134	Elevated Insulin and Insulin Resistance are Associated with Altered Myelin in Cognitively Unimpaired Middleâ€”Aged Adults. <i>Obesity</i> , 2019, 27, 1464-1471.	1.5	19
135	Tauâ€”Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease. <i>Annals of Neurology</i> , 2021, 90, 751-762.	2.8	19
136	Factors Associated with Lumbar Puncture Participation in Alzheimerâ€™s Disease Research. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1559-1567.	1.2	19
137	Interaction of amyloid and tau on cortical microstructure in cognitively unimpaired adults. <i>Alzheimer's and Dementia</i> , 2022, 18, 65-76.	0.4	18
138	Estrogen and Cognition: The Story So Far. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2003, 58, M322-M323.	1.7	17
139	Cognitive response to estradiol in postmenopausal women is modified by high cortisol. <i>Neurobiology of Aging</i> , 2012, 33, 829.e9-829.e20.	1.5	17
140	Longitudinal Assessment of Self- and Informant-Subjective Cognitive Complaints in a Sample of Healthy Late-Middle Aged Adults Enriched with a Family History of Alzheimerâ€™s Disease. <i>Journal of the International Neuropsychological Society</i> , 2017, 23, 617-626.	1.2	17
141	Cardiorespiratory fitness attenuates age-associated aggregation of white matter hyperintensities in an at-risk cohort. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 97.	3.0	17
142	Characterization of Vascular Disease Risk in Postmenopausal Women and Its Association with Cognitive Performance. <i>PLoS ONE</i> , 2013, 8, e68741.	1.1	16
143	Intracranial Arterial 4D Flow in Individuals with Mild Cognitive Impairment is Associated with Cognitive Performance and Amyloid Positivity. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 243-252.	1.2	15
144	NSAIDs may protect against age-related brain atrophy. <i>Frontiers in Aging Neuroscience</i> , 2010, 2, .	1.7	14

#	ARTICLE	IF	CITATIONS
145	Using predictors of hormone therapy use to model the healthy user bias. <i>Menopause</i> , 2012, 19, 524-533.	0.8	14
146	Association of Cardiovascular and Alzheimer's Disease Risk Factors with Intracranial Arterial Blood Flow in Whites and African Americans. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 919-929.	1.2	14
147	Age-Related Tau Burden and Cognitive Deficits Are Attenuated in KLOTHO KL-VS Heterozygotes. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1297-1305.	1.2	14
148	Estrogen and Cognition: A True Relationship?. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 316-318.	1.3	13
149	Cognitive benefits of hormone therapy: Cardiovascular factors and healthy-user bias. <i>Maturitas</i> , 2009, 64, 182-187.	1.0	13
150	Latent Factor Structure and Measurement Invariance of the NIH Toolbox Cognition Battery in an Alzheimer's Disease Research Sample. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 412-425.	1.2	13
151	Cigarette Smoking Status, Cigarette Exposure, and Duration of Abstinence Predicting Incident Dementia and Death: A Multistate Model Approach. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1013-1023.	1.2	13
152	Family history and TOMM40 '523 interactive associations with memory in middle-aged and Alzheimer's disease cohorts. <i>Alzheimer's and Dementia</i> , 2017, 13, 1217-1225.	0.4	12
153	Potential role of estrogen in the pathobiology and prevention of Alzheimer's disease. <i>American Journal of Translational Research (discontinued)</i> , 2009, 1, 131-47.	0.0	12
154	Manifestations of Alzheimer's disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90. <i>Scientific Reports</i> , 2022, 12, 6117.	1.6	12
155	Measuring informed consent capacity in an Alzheimer's disease clinical trial. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2016, 2, 258-266.	1.8	11
156	Effects of Simvastatin on Augmentation Index Are Transient: Outcomes From a Randomized Controlled Trial. <i>Journal of the American Heart Association</i> , 2019, 8, e009792.	1.6	11
157	Association of Cardiovascular Risk Factors with Cerebral Perfusion in Whites and African Americans. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 649-660.	1.2	11
158	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease. <i>Nature Communications</i> , 2022, 13, 1495.	5.8	11
159	An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE- ϵ 4 in female patients with Alzheimer's disease. <i>Nature Aging</i> , 2022, 2, 616-634.	5.3	11
160	Effects of simvastatin on white matter integrity in healthy middle-aged adults. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1656-1667.	1.7	10
161	Age-related differences in white matter microstructure measured by advanced diffusion MRI in healthy older adults at risk for Alzheimer's disease. <i>Aging Brain</i> , 2022, 2, 100030.	0.7	10
162	Does Rural Living in Early Life Increase the Risk for Reduced Cognitive Functioning in Later Life?. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 1171-1182.	1.2	9

#	ARTICLE	IF	CITATIONS
163	In-Depth Site-Specific O-Glycosylation Analysis of Glycoproteins and Endogenous Peptides in Cerebrospinal Fluid (CSF) from Healthy Individuals, Mild Cognitive Impairment (MCI), and Alzheimer's Disease (AD) Patients. <i>ACS Chemical Biology</i> , 2022, 17, 3059-3068.	1.6	9
164	Cardiorespiratory Fitness Modifies Influence of Sleep Problems on Cerebrospinal Fluid Biomarkers in an At-Risk Cohort. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 111-121.	1.2	8
165	Crosswalk study on blood collection tube types for Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12266.	1.2	8
166	Dissection of the polygenic architecture of neuronal A β production using a large sample of individual iPSC lines derived from Alzheimer's disease patients. <i>Nature Aging</i> , 2022, 2, 125-139.	5.3	7
167	Principal components from untargeted cerebrospinal fluid metabolomics associated with Alzheimer's disease biomarkers. <i>Neurobiology of Aging</i> , 2022, 117, 12-23.	1.5	7
168	Impact of apolipoprotein E genotypes on vitamin E and memantine treatment outcomes in Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 344-349.	1.8	6
169	Neurodegeneration, Alzheimer's disease biomarkers, and longitudinal verbal learning and memory performance in late middle age. <i>Neurobiology of Aging</i> , 2021, 102, 151-160.	1.5	6
170	Atorvastatin Therapy is Associated with Greater and Faster Cerebral Hemodynamic Response. <i>Brain Imaging and Behavior</i> , 2008, 2, 94-104.	1.1	5
171	Dementia Trends in the United States. <i>JAMA Internal Medicine</i> , 2017, 177, 58.	2.6	5
172	The Wisconsin Alzheimer's Institute Dementia Diagnostic Clinic Network: A community of practice to improve dementia care. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 2121-2133.	1.3	4
173	CSF sphingomyelin metabolites in Alzheimer's disease, neurodegeneration, and neuroinflammation. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	4
174	Posteromedial hyperactivation during episodic recognition among people with memory decline: findings from the WRAP study. <i>Brain Imaging and Behavior</i> , 2015, 9, 690-702.	1.1	3
175	IC-P-178: Occupational Complexity, Cognitive Reserve, and White Matter Hyperintensities: Findings from The Wisconsin Registry for Alzheimer's Prevention. , 2016, 12, P130-P130.		3
176	[O2-05-06]: GUT MICROBIOME ALTERATIONS IN ALZHEIMER'S DISEASE AND THE RELATIONSHIP WITH CSF BIOMARKERS. <i>Alzheimer's and Dementia</i> , 2017, 13, P563.	0.4	3
177	P1-286: TRANSFORMATION OF CSF BIOMARKER VALUES BETWEEN MEASUREMENT BATCHES. <i>Alzheimer's and Dementia</i> , 2018, 14, P393.	0.4	3
178	P3-271: LUMBAR PUNCTURE SIDE EFFECT RATES IN A RESEARCH SETTING. <i>Alzheimer's and Dementia</i> , 2018, 14, P1180.	0.4	3
179	Predicting Risk for Dementia: Is It Ready for the Clinic?. <i>American Journal of Psychiatry</i> , 2019, 176, 501-502.	4.0	3
180	Assessing Dementia Prevalence in the Wisconsin Longitudinal Study: Cohort Profile, Protocol, and Preliminary Findings. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 751-768.	1.2	3

#	ARTICLE	IF	CITATIONS
181	Insulin resistance is related to cognitive decline but not change in CSF biomarkers of Alzheimer's disease in non-demented adults. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12220.	1.2	3
182	Cardiorespiratory Fitness Associates with Cerebral Vessel Pulsatility in a Cohort Enriched with Risk for Alzheimer's Disease. <i>Brain Plasticity</i> , 2020, 5, 175-184.	1.9	3
183	17 β -Estradiol Reduces Plasma A β 40 for HRT-Na ν e Postmenopausal Women With Alzheimer Disease: A Preliminary Study. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 239-244.	0.6	2
184	O1 ν 01 ν 03: Alzheimer's disease biomarker-based clusters predict amyloid accumulation and cognitive decline in a preclinical cohort: Findings from the wisconsin registry for Alzheimer's prevention (WRAP). <i>Alzheimer's and Dementia</i> , 2015, 11, P123.	0.4	2
185	Positive affect predicts cerebral glucose metabolism in late middle-aged adults. <i>Social Cognitive and Affective Neuroscience</i> , 2017, 12, 993-1000.	1.5	2
186	Measurement batch differences and between-batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12194.	1.2	2
187	CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12167.	1.2	2
188	Neighborhood disadvantage is associated with accelerated cortical thinning and cognitive decline in cognitively unimpaired adults. <i>Alzheimer's and Dementia</i> , 2020, 16, .	0.4	2
189	Amyloid time: Quantifying the onset of abnormal biomarkers and cognitive impairment along the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
190	Diet and <i>APOE</i> as moderators of the relationship between trimethylamine N-oxide and biomarkers of Alzheimer's disease and glial activation. <i>Alzheimer's and Dementia</i> , 2021, 17, e051827.	0.4	2
191	Cardiorespiratory fitness and cognition in persons at risk for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	1.2	2
192	Estrogen, Cognition, and Dementia. <i>Annals of the New York Academy of Sciences</i> , 2005, 1055, 228-228.	1.8	1
193	P4-004: Cardiorespiratory capacity modifies the association between a polygenic risk score and CSF biomarkers in preclinical Alzheimer's disease. , 2015, 11, P766-P766.		1
194	IC-P-063: Alzheimer's disease biomarker-based clusters predict amyloid accumulation and cognitive decline in a preclinical cohort: Findings from the wisconsin registry for Alzheimer's prevention (WRAP). , 2015, 11, P47-P49.		1
195	IC-P-128: Alterations in myelin content are related to cognitive performance in nondemented older adults: Findings from the wisconsin registry for Alzheimer's prevention study. , 2015, 11, P87-P87.		1
196	P1-199: ApoE-e4 is associated with altered myelin content in preclinical ad. , 2015, 11, P425-P425.		1
197	[P2 ν 208]: CSF AND PLASMA LEVELS OF INFLAMMATION DIFFERENTIALLY RELATE TO CNS MARKERS OF ALZHEIMER'S DISEASE PATHOLOGY AND NEURONAL DAMAGE. <i>Alzheimer's and Dementia</i> , 2017, 13, P689.	0.4	1
198	[O3 ν 10 ν 02]: LONGITUDINAL CSF BIOMARKER CHANGES IN MIDDLE-AGED ADULTS AT RISK FOR AD: THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION (WRAP) AND WISCONSIN ADRC COHORTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P923.	0.4	1

#	ARTICLE	IF	CITATIONS
199	[O5â€™01â€™05]: COHORT AND RACE DIFFERENCES IN FACTORS ASSOCIATED WITH ATTRITION IN LONGITUDINAL STUDIES OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1454.	0.4	1
200	Chronotropic Response and Cognitive Function in a Cohort at Risk for Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 56, 351-359.	1.2	1
201	P4â€™23: LESSONS FROM A RESEARCH COLLABORATION WITH THE ONEIDA NATION OF WISCONSIN. Alzheimer's and Dementia, 2019, 15, P1565.	0.4	1
202	MKâ€™240 imaging features, cognitive associations in preclinical Alzheimer's disease and a case with imagingâ€™postmortem correlates. Alzheimer's and Dementia, 2020, 16, e043217.	0.4	1
203	Principal components from untargeted CSF metabolomics associated with tau. Alzheimer's and Dementia, 2020, 16, e046065.	0.4	1
204	The relationship of glucose-stimulated insulin secretion to cerebral glucose metabolism and cognition in healthy middle-aged and older adults. Neurobiology of Aging, 2021, 105, 174-185.	1.5	1
205	CSF metabolites associated with CSF NeuroToolKit biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.4	1
206	CSF amyloid, tau, and neurodegeneration biomarkers are associated with longitudinal cognitive decline in preclinical AD. Alzheimer's and Dementia, 2021, 17, .	0.4	1
207	Relationships between well-being and cognitive function among Native American, Black, and White participants in the Wisconsin Alzheimer's Disease Research Center. Alzheimer's and Dementia, 2021, 17, .	0.4	1
208	Increased adiposity is related to reduced neurite complexity in the hippocampus, fornix, and uncinate fasciculus of cognitively unimpaired adults. Alzheimer's and Dementia, 2021, 17, .	0.4	1
209	The Interaction between Ventricle to Brain Ratio and Serum Klotho on Cognition in Older Adults at Risk for Alzheimer's Disease. Alzheimer's and Dementia, 2021, 17, e058632.	0.4	1
210	The use of transdermal 17Î²-estradiol in the treatment of Alzheimer's disease. , 0, , 80-86.		0
211	P1-229: THE RELATIONSHIP BETWEEN CEREBRAL PERFUSION, AGE, AND APOE4 IN MIDDLE-AGED ADULTS AT RISK FOR ALZHEIMER'S DISEASE. , 2014, 10, P388-P388.		0
212	IC-P-102: THE RELATIONSHIP BETWEEN CEREBRAL PERFUSION, AGE, AND APOE4 IN MIDDLE-AGED ADULTS AT RISK FOR ALZHEIMER'S DISEASE. , 2014, 10, P57-P58.		0
213	IC-P-007: PATTERNS OF [C-11]PIB AMYLOID BURDEN THAT ARE ASSOCIATED WITH CEREBROSPINAL FLUID AD BIOMARKERS IN PEOPLE AT RISK FOR ALZHEIMER'S DISEASE: FINDINGS FROM THE WRAP STUDY. , 2014, 10, P10-P10.		0
214	P3-103: Assessing the significance of insulin resistance on cerebrospinal fluid Alzheimer's disease biomarkers and memory function in people at risk for Alzheimer's disease: Findings from the wisconsin adrc impact cohort. , 2015, 11, P659-P660.		0
215	IC-P-096: Insulin resistance is associated with altered microstructure in the medial temporal lobe and fornix of cognitively healthy APOE4 carriers. , 2015, 11, P66-P67.		0
216	P1-204: Insulin resistance is associated with altered microstructure in the medial temporal lobe and fornix of cognitively healthy ApoE Î¼4 carriers. , 2015, 11, P427-P428.		0

#	ARTICLE	IF	CITATIONS
217	P4-264: Amyloid pathology is associated with extensive myelin alteration in preclinical Alzheimer's disease: New insights into disease process with novel brain imaging. , 2015, 11, P885-P885.		0
218	P2-210: Subjective memory complaints in middle-aged adults with a family history of Alzheimer's disease. , 2015, 11, P573-P574.		0
219	IC-P-015: High amyloid load is associated with episodic memory decline and incident mild cognitive impairment in middle-aged adults in the wisconsin registry for Alzheimer's prevention (WRAP). , 2015, 11, P21-P21.		0
220	IC-03-01: Cardiorespiratory capacity correlates with cerebral blood flow, white matter hyperintensities, and cognition in preclinical Alzheimer's disease. , 2015, 11, P8-P8.		0
221	P4-066: The relationship between intracranial vascular health and metrics of Alzheimer's disease. , 2015, 11, P793-P794.		0
222	IC-P-044: Cardiorespiratory capacity modifies the association between a polygenic risk score and CSF biomarkers in preclinical Alzheimer's disease. , 2015, 11, P37-P38.		0
223	P3-156: Elevated cardiovascular risk is associated with altered myelin content. , 2015, 11, P688-P688.		0
224	P1-023: Cardiorespiratory capacity correlates with cerebral blood flow, white matter hyperintensities, and cognition in preclinical Alzheimer's disease. , 2015, 11, P345-P345.		0
225	O1-07-03: High amyloid load is associated with episodic memory decline and incident mild cognitive impairment in middle-aged adults in the wisconsin registry for Alzheimer's prevention (WRAP). , 2015, 11, P142-P143.		0
226	O1-12-05: Amyloid Deposition in the Posterior Cingulate is Associated with Altered Microstructure in Cognitively Asymptomatic Individuals: Findings From the Wrap Study. Alzheimer's and Dementia, 2016, 12, P207.	0.4	0
227	O5-01-02: Stress is Associated with Greater Insulin Resistance, Higher CSF Phosphorylated TAU, and Decreased Glucose Metabolism in the Medial Temporal Lobe in apoe 4 Carriers. , 2016, 12, P375-P376.		0
228	IC-P-050: MCI Status, Amyloid and TAU Biomarkers, and Composite Cognitive Impairment Scores are Associated with Cogstate Performance in The Wisconsin Registry For Alzheimer's Prevention. Alzheimer's and Dementia, 2016, 12, P41.	0.4	0
229	IC-P-069: Effects of Kibra Polymorphism on White Matter Integrity: Findings from The Wisconsin Registry for Alzheimer's Prevention. Alzheimer's and Dementia, 2016, 12, P54.	0.4	0
230	IC-P-071: Longevity Gene Klotho Alters Apoe4-Related Cortical Thinning: Findings from The Wisconsin Registry for Alzheimer's Prevention. , 2016, 12, P56-P56.		0
231	P1-274: Patterns of In-Vivo Preclinical TAU and Amyloid Burden Using [F-18]THK5351 and [C-11]PIB. , 2016, 12, P521-P522.		0
232	P1-322: Four-Dimensional Arterial Blood Flow Metrics in The Internal Carotid Artery Predict Cognitive Performance and are Associated with CSF Biomarkers in Patients with MCI. Alzheimer's and Dementia, 2016, 12, P548.	0.4	0
233	P1-344: Poor Sleep Quality is Associated with CSF Markers of Amyloid Deposition in Cognitively Healthy Adults at Risk for Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P561.	0.4	0
234	P1-410: Lifetime Recreational Physical Activity is Associated with CSF Amyloid in Cognitively Asymptomatic Adults. Alzheimer's and Dementia, 2016, 12, P591.	0.4	0

#	ARTICLE	IF	CITATIONS
235	ICâ€Pâ€123: Four Dimensional Arterial Blood Flow Metrics in The Internal Carotid Artery Predict Cognitive Performance and Are Associated With CSF Biomarkers in Patients With MCI. Alzheimer's and Dementia, 2016, 12, P91.	0.4	0
236	P3â€084: Effects of Kibra Polymorphism on White Matter Integrity: Findings from the Wisconsin Registry for Alzheimerâ€™s Prevention. Alzheimer's and Dementia, 2016, 12, P850.	0.4	0
237	ICâ€Pâ€195: Patterns of inâ€Vivo Preclinical TAU and Amyloid Burden Using [Fâ€18]THK5351 and [Câ€11]PIB. Alzheimer's and Dementia, 2016, 12, P141.	0.4	0
238	O3-03-02: MCI STATUS, AMYLOID AND TAU BIOMARKERS, AND COMPOSITE COGNITIVE IMPAIRMENT SCORES ARE ASSOCIATED WITH COGSTATE PERFORMANCE IN THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION. , 2016, 12, P285-P286.		0
239	O3â€05â€01: Occupational Complexity, Cognitive Reserve, and White Matter Hyperintensities: Findings from the Wisconsin Registry for Alzheimer's Prevention. Alzheimer's and Dementia, 2016, 12, P294.	0.4	0
240	O3â€09â€01: Distinct Cognitive Trajectories in Late Middleâ€Age and their Associations with Brain Structure and Alzheimer's Disease Biomarkers: Findings from the Wisconsin Registry for Alzheimer's Prevention. Alzheimer's and Dementia, 2016, 12, P306.	0.4	0
241	O5â€01â€05: Longevity Gene <i>KLOTHO</i> Alters <i>APOE4</i>â€Related Cortical Thinning: Findings from the Wisconsin Registry for Alzheimerâ€™s Prevention. Alzheimer's and Dementia, 2016, 12, P377.	0.4	0
242	P4â€335: Postmortem Cerebrovascular Disease and White Matter Pallor are Associated with Lower Antemortem Cerebral Perfusion, Increased White Matter Hyperintensities, and Poor Learning. Alzheimer's and Dementia, 2016, 12, P1162.	0.4	0
243	[ICâ€Pâ€066]: AD FAMILY HISTORY MODULATES EFFECTS OF TOMM40 â€523â€™ POLYâ€™ ON MTL ATROPHY AND HYPOMETABOLISM IN PRECLINICAL AND AD COHORTS. Alzheimer's and Dementia, 2017, 13, P54.	0.4	0
244	[P3â€331]: 4Dâ€FLOW IN THE CEREBRAL ARTERIES PROVIDES UNIQUE INFORMATION ABOUT CEREBROVASCULAR HEALTH BEYOND ISCHEMIC LESION BURDEN AND SIGNIFICANTLY PREDICTS COGNITIVE OUTCOMES. Alzheimer's and Dementia, 2017, 13, P1078.	0.4	0
245	[P3â€423]: REGIONAL DEFICIT IN SLEEPING BRAIN ACTIVITY ASSOCIATED WITH TAU AND AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY MIDDLEâ€AGED ADULTS. Alzheimer's and Dementia, 2017, 13, P1128.	0.4	0
246	[P4â€163]: STATISTICAL ALGORITHMS FOR HARMONIZING BIOMARKER DISTRIBUTIONS ACROSS DIFFERENT COHORTS, SITES AND ASSAYS: APPLICATIONS TO CSF MEASUREMENTS. Alzheimer's and Dementia, 2017, 13, P1322.	0.4	0
247	[P4â€301]: COMPARING COGNITIVE BATTERIES: UNIFORM DATA SET 2 (UDSâ€2) AND UNIFORM DATA SET 3 (UDSâ€3) IN NONâ€HISPANIC WHITE PARTICIPANTS AND THOSE FROM UNDERREPRESENTED GROUPS ENROLLED IN THE WISCONSIN ALZHEIMER'S DISEASE RESEARCH CENTER'S CLINICAL CORE. Alzheimer's and Dementia, 2017, 13, P1405.	0.4	0
248	[ICâ€Pâ€049]: REGIONAL DEFICIT IN SLEEPING BRAIN ACTIVITY ASSOCIATED WITH TAU AND AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY MIDDLEâ€AGED ADULTS. Alzheimer's and Dementia, 2017, 13, P41.	0.4	0
249	[ICâ€Pâ€156]: 4Dâ€FLOW IN THE CEREBRAL ARTERIES PROVIDES UNIQUE INFORMATION ABOUT CEREBROVASCULAR HEALTH BEYOND ISCHEMIC LESION BURDEN AND SIGNIFICANTLY PREDICTS COGNITIVE OUTCOMES. Alzheimer's and Dementia, 2017, 13, P117.	0.4	0
250	[P1â€503]: MODIFIABLE RISK FACTORS MODERATE THE RELATIONSHIP BETWEEN BETAâ€AMYLOID AND LONGITUDINAL COGNITIVE TRAJECTORIES IN THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION STUDY. Alzheimer's and Dementia, 2017, 13, P485.	0.4	0
251	[P1â€526]: THE WRAPâ€AROUND APPROACH: A NOVEL RENTENTION STRATEGY IN THE AAâ€FAIM STUDY. Alzheimer's and Dementia, 2017, 13, P495.	0.4	0
252	[P1â€611]: LIFETIME PHYSICAL ACTIVITY IS ASSOCIATED WITH CSF AMYLOID IN COGNITIVELY ASYMPTOMATIC APOE É4+ ADULTS. Alzheimer's and Dementia, 2017, 13, P530.	0.4	0

#	ARTICLE	IF	CITATIONS
253	[P2â€“123]: ASSOCIATION OF CHOLESTEROL AND CHOLESTEROL METABOLISM GENES WITH COGNITIVE FUNCTION IN A POPULATION ENRICHED FOR A PARENTAL HISTORY OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P654.	0.4	0
254	[O1â€“10â€“01]: EVIDENCE FOR EARLY DETECTION OF CSF BETAâ€“AMYLOID AND TAU AND EFFECT ON LONGITUDINAL COGNITIVE PERFORMANCE IN INDIVIDUALS AT RISK FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P213.	0.4	0
255	[O3â€“11â€“03]: MODERATE INTENSITY PHYSICAL ACTIVITY IS ASSOCIATED WITH CSF BIOMARKERS IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P927.	0.4	0
256	[ICâ€“Paâ€“171]: MODERATE INTENSITY PHYSICAL ACTIVITY ASSOCIATES WITH CSF BIOMARKERS IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P128.	0.4	0
257	[P4â€“286]: A COMPARISON OF METHODS TO MEASURE INTRAâ€“INDIVIDUAL COGNITIVE VARIABILITY IN NONâ€“HISPANIC WHITES AND AFRICAN AMERICANS IN THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION (WRAP). Alzheimer's and Dementia, 2017, 13, P1394.	0.4	0
258	ICâ€“Paâ€“141: NEIGHBORHOOD DISADVANTAGE PREDICTS HIPPOCAMPAL VOLUME AMONG PARTICIPANTS IN THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION. Alzheimer's and Dementia, 2018, 14, P118.	0.4	0
259	O4â€“07â€“06: NEIGHBORHOOD DISADVANTAGE PREDICTS HIPPOCAMPAL VOLUME AMONG PARTICIPANTS IN THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION. Alzheimer's and Dementia, 2018, 14, P1420.	0.4	0
260	ICâ€“Paâ€“103: RELATIONSHIPS BETWEEN Paâ€“TAU AND CHANGES IN MYELIN CONTENT AND COGNITIVE PERFORMANCE. Alzheimer's and Dementia, 2019, 15, P89.	0.4	0
261	P4â€“637: EXAMINING THE ROLE OF CIGARETTE SMOKING AND CESSATION ON COMBINED RISK OF INCIDENT DEMENTIA, NURSING HOME PLACEMENT, AND DEATH IN COGNITIVELY HEALTHY AND MILD COGNITIVELY IMPAIRED ADULTS. Alzheimer's and Dementia, 2019, 15, P1571.	0.4	0
262	ICâ€“Paâ€“109: LOWER ARTERIAL BLOOD FLOW AND HIGHER PULSATILITY INDEX ARE ASSOCIATED WITH NEURONAL INJURY. Alzheimer's and Dementia, 2019, 15, P93.	0.4	0
263	ICâ€“Paâ€“149: DECREASED CORTICAL NEURITE DENSITY AND ORIENTATION DISPERSION IN ALZHEIMER'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2019, 15, P120.	0.4	0
264	ICâ€“Paâ€“081: CSF MARKERS OF NEURODEGENERATION ARE ASSOCIATED WITH QUANTITATIVE T1. Alzheimer's and Dementia, 2019, 15, P72.	0.4	0
265	The evolution of geriatric neurology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 575-584.	1.0	0
266	P4â€“583: MICROSTRUCTURAL ALTERATIONS WITH OLDER AGE EVALUATED USING THE NODDI MODEL IN A LARGE GROUP OF COGNITIVELY UNIMPAIRED INDIVIDUALS. Alzheimer's and Dementia, 2019, 15, P1544.	0.4	0
267	Simvastatin maintains white matter integrity in healthy middleâ€“aged adults with increased risk for Alzheimerâ€™s disease: A secondary analysis of a randomized controlled trial. Alzheimer's and Dementia, 2020, 16, e043408.	0.4	0
268	The interaction of amyloid and tau on decreased cortical neurite density in preclinical Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e043979.	0.4	0
269	Bloodâ€“brain barrier permeability measured by γ -hydroxy β -oxo α -cholestenoic acid in CSF associates with Alzheimerâ€™s pathology biomarkers in cerebrospinal fluid. Alzheimer's and Dementia, 2020, 16, e046582.	0.4	0
270	Chronicity of amyloid: Methods for estimating amyloid onset and clinical research applications. Alzheimer's and Dementia, 2020, 16, e039782.	0.4	0

#	ARTICLE	IF	CITATIONS
271	The Aging Imperative-Innovations in Research, Education, and Care in Geriatric Medicine. Wisconsin Medical Journal, 2018, 117, 92-93.	0.3	0
272	Relationship of insulin resistance and glucose to tau PET positivity. Alzheimer's and Dementia, 2021, 17, .	0.4	0
273	Greater COVID-19 impact for underrepresented racial and ethnic minority groups: A survey study on the Wisconsin Alzheimer's Disease Research Center participants. Alzheimer's and Dementia, 2021, 17, .	0.4	0
274	Age of amyloid onset, but not amyloid accumulation rate, differs across APOE4 carriers vs. non-carriers in three cohorts and three methods. Alzheimer's and Dementia, 2021, 17, .	0.4	0
275	Amyloid status is associated with deficits in connected speech language. Alzheimer's and Dementia, 2021, 17, .	0.4	0
276	Area-level deprivation is associated with rate of memory decline in late life within a community-based cohort. Alzheimer's and Dementia, 2021, 17, .	0.4	0
277	Racial Differences in Associations of Cognitive Health Status With Happiness, Helplessness, and Hopelessness Among Older Adults: An Exploratory Study. Frontiers in Aging Neuroscience, 2022, 14, .	1.7	0